NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today the appointment of Kevin Rakin and Philippe Romagnoli as new members of the Company’s Board of Directors (“Board”) and the promotion of Mike Burshtine to Executive Vice President and Chief Financial Officer and Nissim Mashiach to Executive Vice President and Chief Operating Officer.
